Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR
Authors
Keywords
-
Journal
BLOOD
Volume 133, Issue 2, Pages 147-155
Publisher
American Society of Hematology
Online
2018-11-27
DOI
10.1182/blood-2018-06-860015
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pathways and mechanisms of venetoclax resistance
- (2017) Prithviraj Bose et al. LEUKEMIA & LYMPHOMA
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
- (2016) Saad Z. Usmani et al. BLOOD
- Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study
- (2016) Jesus Berdeja et al. Clinical Lymphoma Myeloma & Leukemia
- Management of Carfilzomib-Associated Cardiac Adverse Events
- (2016) Joseph Mikhael Clinical Lymphoma Myeloma & Leukemia
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
- (2016) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma
- (2015) R Khan et al. LEUKEMIA
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
- (2013) D. Siegel et al. HAEMATOLOGICA
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
- (2013) A Z Badros et al. LEUKEMIA
- Optimizing Treatment Strategies in Myeloma Cast Nephropathy: Rationale for a Randomized Prospective Trial
- (2012) Frank Bridoux et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial
- (2011) Shaji K. Kumar et al. AMERICAN JOURNAL OF HEMATOLOGY
- Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents
- (2010) Maria Roussou et al. LEUKEMIA RESEARCH
- VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study
- (2009) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More